Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Depreciation & Amortization (CF) came in at $2.0 billion in Q2 2026, up 0.82% year-over-year from $1.9 billion in Q2 2025, and down 2.25% quarter-over-quarter from $2.0 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $2.0 billion for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 0.82% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $7.8 billion (up 3.94% YoY), while the FY2025 annual figure was $7.5 billion, up 2.23% from the prior year.
- Depreciation & Amortization (CF) came in at $2.0 billion for Q2 2026 at Johnson & Johnson, down from $2.0 billion in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.0 billion in Q4 2025 to a low of $1.4 billion in Q1 2023.
- Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2023.
- Year-over-year, Depreciation & Amortization (CF) advanced 29.52% in 2023 and retreated 7.86% in 2024.
- Over 5 years, Depreciation & Amortization (CF) stood at $1.8 billion in 2022, then rose by 4.18% to $1.8 billion in 2023, then grew by 2.88% to $1.9 billion in 2024, then increased by 6.07% to $2.0 billion in 2025, then slipped by 2.59% to $2.0 billion in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.0 billion in Q2 2026, $2.0 billion in Q1 2026, and $2.0 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 1.62 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 594.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 3.97 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 40.52 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 26.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 1.96 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Dec 28, 2025 | 2.01 Bn |
| Sep 28, 2025 | 1.78 Bn |
| Jun 29, 2025 | 1.94 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Dec 29, 2024 | 1.90 Bn |
| Sep 29, 2024 | 1.85 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Mar 31, 2024 | 1.82 Bn |
| Dec 31, 2023 | 1.84 Bn |
| Oct 1, 2023 | 1.83 Bn |
| Jul 2, 2023 | 1.93 Bn |
| Apr 2, 2023 | 1.88 Bn |
| Jan 1, 2023 | 1.42 Bn |
| Apr 3, 2022 | 1.77 Bn |
| Oct 3, 2021 | 1.81 Bn |
| Jul 4, 2021 | 1.84 Bn |
| Apr 4, 2021 | 1.89 Bn |
| Jan 3, 2021 | 1.94 Bn |